Novartis Amends MorphoSys Acquisition Filing
Ticker: NVSEF · Form: SC 13D/A · Filed: Jun 10, 2024 · CIK: 1114448
| Field | Detail |
|---|---|
| Company | Novartis Ag (NVSEF) |
| Form Type | SC 13D/A |
| Filed Date | Jun 10, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, amendment, pharmaceuticals
Related Tickers: MOR
TL;DR
Novartis filed an update on its MorphoSys acquisition, deal expected to close soon.
AI Summary
Novartis AG, through its subsidiary Novartis Bidco AG, filed an amendment (No. 2) to its Schedule 13D on June 10, 2024, regarding its acquisition of MorphoSys AG. The filing indicates that Novartis Bidco AG has acquired a significant portion of MorphoSys AG's ordinary shares, with the transaction expected to close in the first half of 2024.
Why It Matters
This filing provides an update on Novartis's ongoing acquisition of MorphoSys AG, a key development in the pharmaceutical sector that could impact the competitive landscape and future drug development.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions and regulatory approvals, which introduces some risk to the completion of the deal.
Key Players & Entities
- Novartis AG (company) — Filing Person (Offeror)
- Novartis Bidco AG (company) — Indirect wholly owned subsidiary of Novartis AG, Filing Person (Offeror)
- MorphoSys AG (company) — Subject Company (Issuer)
- Karen L. Hale (person) — Chief Legal Officer of Novartis AG
FAQ
What is the purpose of this SC 13D/A filing?
This filing is an amendment (No. 2) to the Schedule 13D, providing updated information regarding Novartis AG's acquisition of MorphoSys AG.
Who are the filing persons in this amendment?
The filing persons are Novartis Bidco AG, an indirect wholly owned subsidiary of Novartis AG, and Novartis AG.
What is the subject company of this filing?
The subject company is MorphoSys AG.
What is the title of the class of securities involved?
The title of the class of securities is Ordinary Shares, no Par Value.
When is the acquisition of MorphoSys AG expected to close?
The filing indicates the transaction is expected to close in the first half of 2024.
Filing Stats: 1,847 words · 7 min read · ~6 pages · Grade level 10 · Accepted 2024-06-10 16:30:07
Filing Documents
- tm2410988d25_sc13da.htm (SC 13D/A) — 93KB
- 0001104659-24-070037.txt ( ) — 95KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of their knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: June 10, 2024 Novartis BidCo AG By: /s/ Daniel Weiss /s/ Bertrand Bugnon Name: Daniel Weiss Name: Bertrand Bugnon Title: As Authorized Signatory Title: As Authorized Signatory Novartis Pharma Ag By: /s/ Lukas Foertsch /s/ Luca Hammel Name: Lukas Foertsch Name: Luca Hammel Title: As Authorized Signatory Title: As Authorized Signatory Novartis Ag By: /s/ David Quartner /s/ Tariq ElRafie Name: David Quartner Name: Tariq ElRafie Title: As Attorney Title: As Attorney 7